News stories about CoLucid Pharmaceuticals (NASDAQ:CLCD) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CoLucid Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.6250870984296 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
What are top analysts saying about CoLucid Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CoLucid Pharmaceuticals Inc and related companies.